CompletedPhase 3

Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery

United States148 participantsStarted 2023-01-23

Plain-language summary

This study will compare the use of a dual-agent local analgesic (bupivacaine-meloxicam) for abdominal incisions in patients undergoing retropubic mid-urethral sling surgery to see if narcotic usage and pain are impacted.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * undergoing retropubic mid-urethral sling surgery (with concomitant anterior repair or urethrocele repair) * English as first language Exclusion Criteria: * patients undergoing concomitant posterior repair, vaginal vault suspension, or any other intra-peritoneal surgeries including hysterectomy * NSAID use within 7 days of surgery * steroid use within 10 days * daily opioid use in the last 3 months * long acting opioids within 3 days * any opioids within 24h * patients unable to consent for themselves * patients allergic to meloxicam or bupivacaine * pregnant or lactating patients

What they're measuring

To determine if use of bupivacaine-meloxicam reduces post-operative narcotic use over the first 3 days following surgery

Timeframe: 72 hours post surgery

Trial details

NCT IDNCT05702827

SponsorTriHealth Inc.

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-03-22

View on ClinicalTrials.gov More Stress Urinary Incontinence trials